Research article · 1 Sep 2015
ArticlePublished 2012
Ischemia-Modified Albumin: Its Diagnostic Implications and Shortfalls
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Patients presenting with chief complaint of chest pain or other signs suggestive of acute coronary syndrome (ACS) in hospital is often time-consuming, expensive and problematic to arrive to the definitive diagnosis for the cause of chest pain. Recent research has found that ischemia-modified albumin (IscMA) is an ideal biomarker for ischemia. It is highly sensitive and detectable in the early phase of ACS. Many clinical studies have demonstrated that IscMA can be used for early diagnosis of acute myocardial infarction (AMI), so that the admission rate of non-ischemic patients can be reduced allowing the relieve from the heavy cost burdened on admission to Intensive Coronary Care Unit (ICCU). Ischemia modified albumin which is proposed biomarker for myocardial ischemia is detected within six to ten minutes and remains elevated for up to several hours later. Although, it was thought as an evident biomarker for ischemia process in AMI and ACS, but it’s no doubt that the elevations are also accompanied in various other diseases where the process of ischemia occurs. Studies have surfaced the elevation of IscMA is other diseases too, namely diabetes, hypertension, in smokers, in patients with peripheral vascular disease, skeletal muscle ischemia, end stage renal disease, in cirrhosis of liver, systemic sclerosis, etc. It is the right time to unveil the exact mechanisms of elevation of IscMA which is accompanied in various diseased states. Â
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 15 Mar 2021
The role of ischemia-modified albumin in the detection of coronary slow flow
Research article · 25 Feb 2014
Ischemia-Modified Albumin as a Marker of Myocardium and Skeletal Muscle Damage
Research article · 24 Aug 2022
Effect on ischemia modified albumin in lipitensive patients.
Research article · 2021
Comparative Evaluation of Trimethylamine-N-Oxide, Ischemia Modified Albumin, Iron, and Copper among Normal Control, Obese Metabolically Healthy and Obese with Metabolic Syndrome: A Cross-Sectional Biochemical Analysis at Tertiary Care Hospital in Udupi District
More from this journal
The newest in Journal of Biomedical Sciences.
Commentary · 24 Dec 2024
Tissue Engineering: Innovations in Artificial Organs
Commentary · 24 Dec 2024
Role of Systems Biology in Understanding Complex Diseases
Commentary · 24 Dec 2024
The Promise and Challenges of Gene Therapy in Treating Genetic Disorders
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biomedical Sciences
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Arun Kumar”

